Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-BX102 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JAB-BX102 + pembrolizumab is an investigational combination therapy for advanced solid tumors, currently in early-stage clinical trials. JAB-BX102 is a humanized monoclonal antibody targeting CD73, an ectoenzyme that drives immunosuppression in the tumor microenvironment via the adenosine pathway. Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor targeting PD-1 (programmed cell death protein 1), widely used in immuno-oncology. The rationale for this combination is that inhibition of CD73 can reduce adenosine-mediated immunosuppression and enhance the anti-tumor immune response triggered by PD-1 blockade. Developed collaboratively by Jacobio and Merck & Co., this combination is being tested for safety, tolerability, and preliminary antitumor activity in adults with refractory or metastatic solid tumors[1][2][3][7].
- Brand names
- KEYTRUDA
- Other names
- JAB-BX102 + KEYTRUDA
02
Targets
NT5E (Cluster of Differentiation 73)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on JAB-BX102 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-BX102 + pembrolizumab.